Clinical trials: Inadequate Response
Psoriatic Arthritis
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
The purpose of this study is to compare the safety and efficacy of risankizumab versus placebo in participants with moderately to severely active psoriatic arthritis (PsA).
- Trial name
- KEEPsAKE 1 (NCT03675308)
- Testing
- Risankizumab
- Where
- 256 sites in United States, Argentina and 37 more
- Volunteers
- 964 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
PK, PD, Safety, and Efficacy of SAIT101 Versus MabThera® Versus Rituxan® in Patients With Rheumatoid Arthritis
A randomised, double blind, parallel group, multicentre study yo compare the pharmacokinetics, pharmacokinetics, safety and efficacy of SAIT101 versus MabThera® versus Rituxan® in patients with rheumatoid arthritis.
- Trial name
- NCT02819726
- Testing
- SAIT101, MabThera, Rituxan
- Where
- 75 sites in United States, Bosnia and Herzegovina and 9 more
- Volunteers
- 294 people
- Sponsor
- Archigen Biotech Limited
Major Depressive Disorder
Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder
To evaluate the efficacy of quetiapine fumarate sustained release (Seroquel SR™) in combination with an antidepressant versus an antidepressant alone in patients with Major Depressive Disorder.
- Trial name
- ONYX (NCT00351910)
- Testing
- Quetiapine, Amitriptyline, Bupropion
- Where
- 72 sites in Australia, Belgium and 10 more
- Volunteers
- 494 people
- Sponsor
- AstraZeneca
Primary Biliary Cirrhosis
Study of Obeticholic Acid（OCA） Combination With Ursodeoxycholic Acid (UDCA) in Patients With Primay Biliary Cirrhosis (PBC)
Obecholic acid is a modified bile acid and Farnesoid X receptor (FXR) agonist. FXR is a key regulator of bile acid synthesis and transport. Bile acids are used by the body to help with digestion.
- Trial name
- NCT04956328
- Testing
- Obeticholic Acid Tablets, UDCA
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Rheumatoid Arthritis
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 in Participants With Rheumatoid Arthritis (MK-8457-010)
The purpose of this study is to assess the safety and efficacy of MK-8457 + Methotrexate (MTX) in participants with active rheumatoid arthritis (RA) and an inadequate response or intolerance to anti-tumor necrosis factor α…
- Trial name
- NCT01651936
- Testing
- MK-8457 100 mg, Methotrexate
- Volunteers
- 56 people
- Sponsor
- Merck Sharp & Dohme LLC
Rheumatoid Arthritis (RA)
Changes in Ultrasonographic Assessment of Inflammation Upon Initiation of Adalimumab Combination Therapy in Chinese Rheumatoid Arthritis (RA) Patients With Inadequate Response to Methotrexate
Prospective, post-marketing, multi-center, open-label study to explore if the initiation of adalimumab could influence grey-scale (GS) and power Doppler (PD) ultrasonographic (US) score using 36-joint plus 4-tendon scoring…
- Trial name
- NCT02786563
- Where
- 4 sites in China
- Sponsor
- AbbVie
Active Systemic Lupus Erythematosus
Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus
The primary objective is to evaluate the efficacy and safety of efavaleukin alfa in subjects with active systemic lupus erythematosus.
- Trial name
- NCT04680637
- Testing
- Efavaleukin Alfa, Standard of Care
- Where
- 150 sites in United States, Austria and 17 more
- Volunteers
- 168 people
- Sponsor
- Amgen
Depressive Disorder, Major
A Standard of Care Study of Patients With Major Depressive Disorder Who Have Had an Inadequate Response to a Selective Serotonin Reuptake/Serotonin-Norepinephrine Reuptake Inhibitor Antidepressant
The purpose of this study is to assess the safety (adverse events, serious adverse events, deaths, suicidality) of participants with major depressive disorder (MDD) treated according to the standard of care (SOC).
- Trial name
- NCT05109195
- Testing
- Standard of Care (SOC)
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 7 people
- Sponsor
- Janssen Research & Development, LLC
Arthritis, Rheumatoid
Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
This study [contRAst 1 (201790: NCT03980483)] is a phase 3, randomized, multicenter, double blind study to assess the safety and efficacy of GSK3196165, in combination with methotrexate (MTX), for the treatment of adult…
- Trial name
- contRAst 1 (NCT03980483)
- Testing
- GSK3196165 (Otilimab), Tofacitinib 5 mg
- Where
- 76 sites in China, Hungary and 8 more
- Volunteers
- 1,537 people
- Sponsor
- GlaxoSmithKline
Rheumatoid Arthritis (RA)
Masitinib in Refractory Active Rheumatoid Arthritis
The objective is to compare efficacy and safety of masitinib at 3 and 6 mg/kg/day to methotrexate, with a randomisation 1:1:1, in treatment of patients with active rheumatoid arthritis with inadequate response to 1.
- Trial name
- NCT01410695
- Testing
- masitinib 3 mg, masitinib 6.0 mg, methotrexate
- Where
- Czechia
- Volunteers
- 324 people
- Sponsor
- AB Science
Idiopathic Intracranial Hypertension (IIH)
Venous Stenting Evaluation in Patients With Intracranial Hypertension Under Long-term Acetazolamide
This study is aimed at patients suffering from long term intracranial hypertension (caracterized by visual loss, chronic headache and/or tinnitus), receiving acetazolamide for more than 1 year, having inadequate response to…
- Trial name
- DIVEIINLATE (NCT06945848)
- Testing
- Acetazolamide, Stent (Tentos 4F or Precise ProRX)
- Where
- 3 sites in France
- Volunteers
- 114 people
- Sponsor
- University Hospital, Montpellier
Major Depressive Disorder
Safety and Efficacy Study Comparing ETS6103 With Amitriptyline in the Treatment of Major Depressive Disorder (MDD)
To demonstrate that the antidepressant activity of ETS6103 is not inferior to amitriptyline in subjects who have an unsatisfactory response to / are resistant to treatment with SSRIs.
- Trial name
- ETS6103-003 (NCT02014363)
- Testing
- ETS6103 (low dose), ETS6103 (high dose), Amitriptyline
- Where
- United Kingdom
- Volunteers
- 164 people
- Sponsor
- e-Therapeutics PLC
Rheumatoid Arthritis
Study to Investigate the Efficacy, Safety, and Tolerability of FBL-MTX in Patients With Rheumatoid Arthritis
The goal of this clinical trial is to evaluate the efficacy of FBL-MTX administered by subcutaneous route in Rheumatoid Arthritis patients.
- Trial name
- NCT06565273
- Testing
- FBL-MTX
- Where
- 8 sites in Portugal
- Volunteers
- 40 people
- Sponsor
- SOLFARCOS - Pharmaceutical and Cosmetic Solutions Ltd
Rheumatoid Arthritis
A Phase 2 Study to Evaluate the Safety and Efficacy of YRA-1909 in Patients With Rheumatoid Arthritis
This is a multicenter, randomized, double-blind phase2 study to evaluate the safety and investigate the efficacy of YRA-1909 in Patients with Rheumatoid Arthritis who are on a stable dose of Methotrexate(MTX) and who have an…
- Trial name
- NCT03275025
- Testing
- YRA-1909 low dose, YRA-1909 mid dose, YRA-1909 high dose
- Where
- 14 sites in South Korea
- Volunteers
- 116 people
- Sponsor
- Yungjin Pharm. Co., Ltd.
Rheumatoid Arthritis
A Study of The Effect of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate on Articular Damage in The Hand in Patients With Moderate to Severe Rheumatoid Arthritis Who Have an Inadequate Response to Non-Biological DMARDs
This open-label, single arm study will evaluate the effect of RoActemra/Actemra in combination with methotrexate on articular damage in the hand (synovitis/osteitis and erosions) in patients with moderate to severe rheumatoid…
- Trial name
- NCT01878318
- Testing
- methotrexate, tocilizumab [RoActemra/Actemra]
- Sponsor
- Hoffmann-La Roche
Psoriatic Arthritis
A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug
This is a Phase 3 multicenter study that included two periods. Period 1 was designed to compare the safety, tolerability, and efficacy of upadacitinib 15 mg once daily (QD) and 30 mg QD versus placebo in participants with…
- Trial name
- SELECT - PsA 2 (NCT03104374)
- Testing
- Upadacitinib
- Where
- 165 sites in United States, Australia and 17 more
- Volunteers
- 642 people
- Sponsor
- AbbVie
Eosinophilic Duodenitis, Eosinophilic Gastroenteritis
A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis
This is a Phase 3, multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of lirentelimab (AK002) given monthly for 6 doses in adult patients with active eosinophilic duodenitis.
- Trial name
- EoDyssey (NCT04856891)
- Testing
- AK002
- Where
- 39 sites in United States
- Volunteers
- 94 people
- Sponsor
- Allakos Inc.
Rheumatoid Arthrits
A Study to Evaluate the Efficacy and Safety of Proximod in Patients With Rheumatoid Arthritis
This study is to evaluate the efficacy and safety of different doses of proximod in moderate-to-severe active rheumatoid arthritis subjects with inadequate response or intolerance to bDMARDs and/or tsDMARDs
- Trial name
- NCT07856511
- Testing
- Proximod
- Volunteers
- 590 people
- Sponsor
- Jiankuan (Suzhou) Biotechnology Company Limited
Multiple Myeloma, Non-Hodgkins Lymphoma
Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant
Plerixafor, administered at a dose of 240 ug/kg, potentiates the effect of granulocyte colony-stimulating factor (G-CSF) to increase peripheral blood progenitor cells in both healthy volunteers and cancer patients.
- Conditions
- Multiple Myeloma, Non-Hodgkins Lymphoma, Hodgkins Disease
- Trial name
- NCT00901225
- Testing
- G-CSF plus Plerixafor
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Duke University
Major Depressive Disorder (MDD)
Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy
The objectives of this exploratory trial are to evaluate the efficacy, safety, and subjects' subjective satisfaction when switching to adjunctive brexpiprazole in subjects with MDD who have responded inadequately to preceding…
- Trial name
- NCT02012218
- Testing
- ADT, Brexpiprazole
- Where
- 24 sites in United States
- Volunteers
- 61 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.